Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Daniel M. Girardi"'
Autor:
Gustavo S. Fernandes, Daniel M. Girardi, João Paulo G. Bernardes, Felipe P. Fonseca, Eduardo R. Fregnani
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
Abstract Background Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case
Externí odkaz:
https://doaj.org/article/95d669a6298e4516b0ed4ef54d6dc9ce
Autor:
Daniel M. Girardi, Mariana A. de Lima, Gabriel C. B. Pereira, Marcelo V. Negrão, Rossana V. M. López, Fernanda C. Capareli, Jorge Sabbaga, Paulo Marcelo G. Hoff
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Treatment of localized gastric cancer (LGC) consists of surgical resection followed by adjuvant treatment. Both chemoradiation (CRT) and chemotherapy (CT) regimens have shown benefit in survival outcomes versus observation. Howeve
Externí odkaz:
https://doaj.org/article/76bb3fdc7ade44489835116eec73b541
Autor:
Andrea B. Apolo, Jane B. Trepel, Liang Cao, Donald P. Bottaro, Yang-Min Ning, Howard L. Parnes, Elad Sharon, John J. Wright, Howard Streicher, Antoun Toubaji, Maria Merino, William D. Figg, Vladimir Valera, Heather J. Chalfin, Sandeep Gurram, Yunkai Yu, Sunmin Lee, Min-Jung Lee, Keith S. Chan, Rene Costello, Seth M. Steinberg, Bernadette Redd, Hadi Bagheri, Carlos Diaz, Jacqueline Cadena, Olena Sierra Ortiz, Lisa Ley, Lisa Cordes, Biren Saraiya, Sumanta K. Pal, Primo Lara, Rosa Nadal, Amir Mortazavi, Scot A. Niglio, Daniel M. Girardi
Supplementary Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91fac2839c0f806f56fe1cbb014c15e7
https://doi.org/10.1158/1078-0432.22486583.v1
https://doi.org/10.1158/1078-0432.22486583.v1
Autor:
Andrea B. Apolo, Jane B. Trepel, Liang Cao, Donald P. Bottaro, Yang-Min Ning, Howard L. Parnes, Elad Sharon, John J. Wright, Howard Streicher, Antoun Toubaji, Maria Merino, William D. Figg, Vladimir Valera, Heather J. Chalfin, Sandeep Gurram, Yunkai Yu, Sunmin Lee, Min-Jung Lee, Keith S. Chan, Rene Costello, Seth M. Steinberg, Bernadette Redd, Hadi Bagheri, Carlos Diaz, Jacqueline Cadena, Olena Sierra Ortiz, Lisa Ley, Lisa Cordes, Biren Saraiya, Sumanta K. Pal, Primo Lara, Rosa Nadal, Amir Mortazavi, Scot A. Niglio, Daniel M. Girardi
Purpose:This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI).Patients and Methods:A phase I expansion coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35680e61fde6720351d13f1d7642bf4a
https://doi.org/10.1158/1078-0432.c.6532346
https://doi.org/10.1158/1078-0432.c.6532346
Autor:
Daniel M. Girardi, Jana Priscila M. Pacífico, Fernanda P. L. Guedes de Amorim, Gustavo dos Santos Fernandes, Marcela C. Teixeira, Allan A. L. Pereira
Publikováno v:
Pharmaceuticals, Vol 14, Iss 1, p 28 (2020)
Advanced hepatocellular carcinoma is a prevalent and potentially aggressive disease. For more than a decade, treatment with sorafenib has been the only approved therapeutic approach. Moreover, no agent has been proven to prolong survival following th
Externí odkaz:
https://doaj.org/article/9f8ed28d07f44984b64e433be5bcd18b
Autor:
Daniel M. Girardi, Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal, Biren Saraiya, Lisa Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Hadi Bagheri, Bernadette Redd, Seth M. Steinberg, Rene Costello, Keith S. Chan, Min-Jung Lee, Sunmin Lee, Yunkai Yu, Sandeep Gurram, Heather J. Chalfin, Vladimir Valera, William D. Figg, Maria Merino, Antoun Toubaji, Howard Streicher, John J. Wright, Elad Sharon, Howard L. Parnes, Yang-Min Ning, Donald P. Bottaro, Liang Cao, Jane B. Trepel, Andrea B. Apolo
Publikováno v:
Clinical Cancer Research. 28:1353-1362
Purpose: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). Patients and Methods: A phase I expansion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a052a8ee13fc91996589c4bbfe769d83
https://doi.org/10.1158/1078-0432.ccr-21-3726
https://doi.org/10.1158/1078-0432.ccr-21-3726
Autor:
Daniel M. Girardi, Lara P. Sousa, Thiago A. Miranda, Fernanda N. C. Haum, Gabriel C. B. Pereira, Allan A. L. Pereira
Publikováno v:
Cancers. 15:1680
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f18b7fb59f9b81710de9d74b6fa9dc72
https://doi.org/10.3390/cancers15061680
https://doi.org/10.3390/cancers15061680
Autor:
Gustavo S. Fernandes, Daniel F. Marques, Daniel M. Girardi, Maria Ignez F. Braghiroli, Renata A. Coudry, Sibele I. Meireles, Artur Katz, Paulo M. Hoff
Publikováno v:
Clinics, Vol 72, Iss 10, Pp 588-594
OBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pre
Externí odkaz:
https://doaj.org/article/112b02f54ea548fbbd24de7147338e53
Autor:
Girardi, Daniel M.1,2 (AUTHOR) daniel.mgirardi@hsl.org.br, Sousa, Lara P.3 (AUTHOR), Miranda, Thiago A.3 (AUTHOR), Haum, Fernanda N. C.3 (AUTHOR), Pereira, Gabriel C. B.1,2 (AUTHOR), Pereira, Allan A. L.1,2 (AUTHOR)
Publikováno v:
Cancers. Mar2023, Vol. 15 Issue 6, p1680. 23p.
Publikováno v:
Immunotherapy Weekly; 7/23/2024, p892-892, 1p